Ask OpenScientist

Ask a research question about Alternating Hemiplegia of Childhood. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
4
Pathophys.
8
Phenotypes
7
Pathograph
1
Genes
3
Treatments
2
Differentials
1
Datasets
3
Trials
3
References
1
Deep Research
👪

Inheritance

1
Autosomal dominant with predominantly de novo ATP1A3 variants HP:0000006
Alternating hemiplegia of childhood is part of the autosomal dominant ATP1A3-related disorder spectrum. Most individuals with the severe AHC phenotype have de novo heterozygous ATP1A3 pathogenic variants, but rare familial inheritance and parental gonadal or somatic-gonadal mosaicism mean recurrence counseling should include parental testing and residual sibling recurrence risk above the general population rate.
Autosomal dominant inheritance De novo rate: Most AHC cases
Show evidence (4 references)
PMID:20301294 SUPPORT Human Clinical
"ATP1A3-related disorder – including the four historically defined phenotypes of AHC, CAPOS syndrome, RECA/FIPWE, and RDP – is inherited in an autosomal dominant manner."
GeneReviews establishes autosomal dominant inheritance for the broader ATP1A3-related disorder spectrum that includes AHC.
PMID:20301294 SUPPORT Human Clinical
"Most individuals with a more severe ATP1A3-related phenotype (e.g., AHC) have the disorder as the result of a de novo pathogenic variant."
GeneReviews identifies de novo pathogenic variants as the typical origin for the severe AHC phenotype.
PMID:22842232 SUPPORT Human Clinical
"This work identifies de novo ATP1A3 mutations as the primary cause of AHC"
The original ATP1A3 discovery cohort supports de novo ATP1A3 variants as the primary cause of AHC.
+ 1 more reference

Pathophysiology

4
ATP1A3-dependent neuronal membrane transport dysfunction
Pathogenic ATP1A3 variants impair the neuronal alpha-3 subunit of the P-type sodium:potassium-exchanging transporter, weakening ATPase function and disrupting maintenance of transmembrane ionic gradients.
neuron link
establishment or maintenance of transmembrane electrochemical gradient link ↕ DYSREGULATED
P-type sodium:potassium-exchanging transporter activity link
Show evidence (2 references)
PMID:22842232 SUPPORT In Vitro
"AHC-causing mutations in this gene caused consistent reductions in ATPase activity without affecting the level of protein expression."
Directly supports ATP1A3 hypofunction as the molecular lesion in AHC.
PMID:25996915 SUPPORT Human Clinical
"Mutations in ATP1A3 cause Alternating Hemiplegia of Childhood (AHC) by disrupting function of the neuronal Na+/K+ ATPase."
Supports the core ATP1A3 membrane-transport mechanism.
Paroxysmal motor and oculomotor network instability
ATP1A3 pump failure produces episodic instability in motor and oculomotor circuits, yielding hemiplegic attacks, dystonia, nystagmus, and autonomic spell clustering.
neuron link
neuronal action potential link ↕ DYSREGULATED
brainstem link cerebral cortex link
Show evidence (2 references)
PMID:35945798 SUPPORT Human Clinical
"Alternating Hemiplegia of Childhood (AHC) is a rare disorder with onset in the first 18 months of life characterized by stereotyped paroxysmal manifestations of tonic and dystonic attacks, nystagmus with other oculomotor abnormalities, respiratory and autonomic dysfunctions."
Supports a paroxysmal motor and oculomotor circuit phenotype.
PMID:24821639 SUPPORT Human Clinical
"The variability of individual clinical presentations and evolution of symptoms have made diagnosis difficult."
Supports variable paroxysmal presentations that reflect circuit-level instability.
Epileptogenic cortical network dysfunction
AHC can produce focal or generalized seizures, status epilepticus, and nonepileptic reduced-awareness spells that require EEG-based distinction.
neuron link
neuronal action potential link ↕ DYSREGULATED
cerebral cortex link
Show evidence (2 references)
PMID:31484714 SUPPORT Human Clinical
"Thirty-two of 51 patients had epilepsy: 18 focal seizures, frontal more frequently than temporal, and then posterior."
Supports common epileptogenic involvement in AHC.
PMID:31484714 SUPPORT Human Clinical
"EEG may become epileptiform only on follow-up."
Supports the need for longitudinal EEG assessment when epilepsy is suspected.
Chronic neurodevelopmental impairment
Recurrent attacks, epilepsy, and ATP1A3 dysfunction converge on persistent cognitive, motor, and behavioral disability.
neuron link
cerebellum link cerebral cortex link
Show evidence (3 references)
PMID:25996915 SUPPORT Human Clinical
"Patients with an E815K mutation demonstrate an earlier age of onset, more severe motor impairment and a higher prevalence of status epilepticus."
Supports persistent severe neurologic impairment in a well-characterized AHC subgroup.
PMID:36192182 SUPPORT Human Clinical
"All patients had cognitive impairment."
Supports chronic neurodevelopmental impairment across ATP1A3-related disease.
PMID:35945798 SUPPORT Human Clinical
"Some disorders caused by ATP1A3 variants have been defined as ATP1A3-related disorders"
Supports overlap between AHC and broader ATP1A3-related neurodevelopmental disability.

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Alternating Hemiplegia of Childhood Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.

Phenotypes

8
Eye 1
Nystagmus FREQUENT Nystagmus (HP:0000639)
Show evidence (1 reference)
PMID:24821639 SUPPORT Human Clinical
"the common earliest manifestations are dystonic or tonic attacks and nystagmus."
Supports nystagmus as an early clue to AHC.
Nervous System 6
Global developmental delay FREQUENT Global developmental delay (HP:0001263)
Show evidence (1 reference)
PMID:35945798 SUPPORT Human Clinical
"AHC is often associated with epileptic seizures and developmental delay."
Supports developmental delay as a common non-paroxysmal feature.
Dystonia FREQUENT Dystonia (HP:0001332)
Show evidence (1 reference)
PMID:35945798 SUPPORT Human Clinical
"Alternating Hemiplegia of Childhood (AHC) is a rare disorder with onset in the first 18 months of life characterized by stereotyped paroxysmal manifestations of tonic and dystonic attacks, nystagmus with other oculomotor abnormalities, respiratory and autonomic dysfunctions."
Supports dystonia as a typical paroxysmal manifestation.
Seizure FREQUENT Seizure (HP:0001250)
Show evidence (1 reference)
PMID:31484714 SUPPORT Human Clinical
"Thirty-two of 51 patients had epilepsy: 18 focal seizures, frontal more frequently than temporal, and then posterior."
Supports seizure/epilepsy as a frequent AHC phenotype.
Autonomic dysfunction FREQUENT Abnormality of the autonomic nervous system (HP:0002270)
Show evidence (1 reference)
PMID:35945798 SUPPORT Human Clinical
"Alternating Hemiplegia of Childhood (AHC) is a rare disorder with onset in the first 18 months of life characterized by stereotyped paroxysmal manifestations of tonic and dystonic attacks, nystagmus with other oculomotor abnormalities, respiratory and autonomic dysfunctions."
Supports autonomic dysfunction as a core feature included in the attack phenotype.
Ataxia FREQUENT Ataxia (HP:0001251)
Show evidence (1 reference)
PMID:38043964 SUPPORT Human Clinical
"pervasive neurological disabilities (e.g., developmental delay, learning disabilities, choreoathetosis, and ataxia)."
Supports ataxia as a chronic non-paroxysmal manifestation of AHC.
Choreoathetosis FREQUENT Choreoathetosis (HP:0001266)
Show evidence (1 reference)
PMID:38043964 SUPPORT Human Clinical
"pervasive neurological disabilities (e.g., developmental delay, learning disabilities, choreoathetosis, and ataxia)."
Supports choreoathetosis as a chronic non-paroxysmal manifestation of AHC.
Other 1
Episodic hemiplegia VERY_FREQUENT Episodic hemiplegia (HP:0012194)
Show evidence (1 reference)
PMID:38043964 SUPPORT Human Clinical
"Alternating hemiplegia of childhood (AHC) is characterized by recurrent episodes of hemiplegia which may alternate sides between attacks."
Directly supports the core paroxysmal hemiplegic phenotype.
🧬

Genetic Associations

1
ATP1A3 (Causative)
Show evidence (2 references)
PMID:22842232 SUPPORT Human Clinical
"This work identifies de novo ATP1A3 mutations as the primary cause of AHC"
Supports ATP1A3 as the main causative gene and de novo mutation as the typical mode of occurrence.
PMID:25996915 SUPPORT Human Clinical
"Of 143 simplex occurrences, 58 had D801N (40%), 38 had E815K(26%) and 11 had G947R (8%) mutations [corrected]."
Supports the recurrent ATP1A3 variant spectrum in a large AHC cohort.
💊

Treatments

3
Flunarizine prophylaxis
Action: Pharmacotherapy NCIT:C15986
Flunarizine is the most commonly used preventive medication for reducing the frequency and intensity of paroxysmal events in AHC.
Show evidence (2 references)
PMID:38043964 SUPPORT Human Clinical
"flunarizine remains the treatment of choice."
Supports flunarizine as the main preventive pharmacotherapy used in AHC.
PMID:35945798 SUPPORT Human Clinical
"Flunarizine is the most commonly used drug for reducing the frequency and intensity of paroxysmal events."
Supports flunarizine as standard preventive therapy.
Supportive trigger avoidance and sleep induction
Action: supportive care MAXO:0000950
Trigger avoidance and rapid sleep induction are practical nonpharmacologic measures used to abort or reduce attacks.
Show evidence (1 reference)
PMID:38043964 SUPPORT Human Clinical
"Management of patients with AHC includes the rapid induction of sleep during paroxysmal attacks and the avoidance of identified triggers."
Supports core supportive management for acute attacks.
Antiseizure therapy
Action: Pharmacotherapy NCIT:C15986
Anti-seizure medication is used when epilepsy is present, although seizures are frequently drug resistant and may require escalation.
Target Phenotypes: seizure
Show evidence (1 reference)
PMID:31484714 SUPPORT Human Clinical
"Nineteen patients (59%) were drug resistant."
Supports the need for seizure-directed therapy in AHC-associated epilepsy.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Alternating Hemiplegia of Childhood:

Familial hemiplegic migraine Not Yet Curated MONDO:0000700
Overlapping Features Familial hemiplegic migraine overlaps with AHC through episodic hemiplegia and ATP1A2/ATP1A3 involvement, but headache-predominant attacks and the broader infantile AHC phenotype favor FHM only when migraine features dominate.
Distinguishing Features
  • Migraine aura and headache are more prominent in familial hemiplegic migraine.
  • AHC typically begins before 18 months and includes sleep-resolving, trigger-sensitive attacks with dystonia and nystagmus.
Show evidence (1 reference)
PMID:22842232 SUPPORT Human Clinical
"the clinical presentation of some of the family members with the ATP1A2 mutation was more consistent with familial hemiplegic migraine"
Supports familial hemiplegic migraine as an important AHC mimic/overlap diagnosis.
Overlapping Features AHC attacks may be mistaken for epilepsy, but video-EEG often shows that some spells are nonepileptic and that epileptiform abnormalities may appear only later.
Distinguishing Features
  • Some AHC spells have no concomitant EEG change.
  • Hemiplegic attacks with sleep-related resolution and prominent dystonia point away from primary epilepsy.
Show evidence (2 references)
PMID:31484714 SUPPORT Human Clinical
"Epileptic seizures may be the first paroxysmal symptom."
Supports epilepsy as a close clinical mimic during early presentation.
PMID:31484714 SUPPORT Human Clinical
"captured RAS showed no concomitant EEG changes"
Supports nonepileptic spell differentiation by video-EEG.
📊

Related Datasets

1
Alternating Hemiplegia of Childhood: Retrospective Genetic Study and Genotype-Phenotype Correlations in 187 Subjects from the US AHCF Registry PMID:25996915
Registry-derived human clinical cohort used for retrospective genotype-phenotype correlation and ATP1A3 mutation analysis in 187 AHC subjects.
human PHENOPACKETS n=187
Conditions: US AHCF registry cohort alternating hemiplegia of childhood
PMID:25996915
Show evidence (1 reference)
PMID:25996915 SUPPORT Human Clinical
"We performed mutation analysis and retrospective genotype-phenotype correlations in all eligible patients with AHC enrolled in the US AHC Foundation registry from 1997-2012."
Directly supports the registry cohort as a curated AHC dataset.
🔬

Clinical Trials

3
NCT02408354 PHASE_II COMPLETED
Randomized crossover trial testing triheptanoin oil for ATP1A3-related AHC.
Show evidence (1 reference)
clinicaltrials:NCT02408354 SUPPORT Human Clinical
"The purpose of this project is to study the efficacy of triheptanoin oil in patients with Alternating Hemiplegia of Childhood (AHC) due to ATP1A3 gene mutation."
Supports a disease-specific interventional trial in AHC.
NCT06248645 PHASE_II RECRUITING
Randomized crossover study of high-flow oxygen for acute dystonic and plegic attacks in ATP1A3-related AHC.
Show evidence (1 reference)
clinicaltrials:NCT06248645 SUPPORT Human Clinical
"The aim of the study is to assess the effect of high-flow oxygen administration (against placebo) as an acute treatment of dystonic and plegic attacks."
Supports ongoing evaluation of an acute AHC attack treatment.
NCT03857607 NOT_APPLICABLE UNKNOWN
Observational natural-history study of ATP1A3-related disease in a UK-wide cohort.
Show evidence (1 reference)
clinicaltrials:NCT03857607 SUPPORT Human Clinical
"An observational study aiming to study the natural history of a UK-wide patient cohort with ATP1A3-related disease."
Supports observational natural-history characterization of ATP1A3-related disease.
{ }

Source YAML

click to show
name: Alternating Hemiplegia of Childhood
creation_date: "2026-04-16T18:42:24Z"
updated_date: "2026-04-16T21:20:00Z"
category: Mendelian
description: >-
  Alternating hemiplegia of childhood is a rare early-onset neurologic disorder
  characterized by recurrent episodes of hemiplegia, paroxysmal dystonia,
  oculomotor abnormalities, developmental delay, and epilepsy. Most cases are
  caused by pathogenic variants in ATP1A3, which impair neuronal sodium-
  potassium transport and destabilize excitability in motor and autonomic
  networks.
disease_term:
  preferred_term: alternating hemiplegia of childhood
  term:
    id: MONDO:0016241
    label: alternating hemiplegia of childhood
parents:
- channelopathy
- neurodevelopmental disorder
- movement disorder
synonyms:
- AHC
- alternating hemiplegia
inheritance:
- name: Autosomal dominant with predominantly de novo ATP1A3 variants
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  de_novo_rate: Most AHC cases
  description: >-
    Alternating hemiplegia of childhood is part of the autosomal dominant
    ATP1A3-related disorder spectrum. Most individuals with the severe AHC
    phenotype have de novo heterozygous ATP1A3 pathogenic variants, but rare
    familial inheritance and parental gonadal or somatic-gonadal mosaicism mean
    recurrence counseling should include parental testing and residual sibling
    recurrence risk above the general population rate.
  evidence:
  - reference: PMID:20301294
    reference_title: "ATP1A3-Related Disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ATP1A3-related disorder – including the four historically defined phenotypes of AHC, CAPOS syndrome, RECA/FIPWE, and RDP – is inherited in an autosomal dominant manner."
    explanation: >-
      GeneReviews establishes autosomal dominant inheritance for the broader
      ATP1A3-related disorder spectrum that includes AHC.
  - reference: PMID:20301294
    reference_title: "ATP1A3-Related Disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most individuals with a more severe ATP1A3-related phenotype (e.g., AHC) have the disorder as the result of a de novo pathogenic variant."
    explanation: >-
      GeneReviews identifies de novo pathogenic variants as the typical origin
      for the severe AHC phenotype.
  - reference: PMID:22842232
    reference_title: De novo mutations in ATP1A3 cause alternating hemiplegia of childhood.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This work identifies de novo ATP1A3 mutations as the primary cause of AHC"
    explanation: >-
      The original ATP1A3 discovery cohort supports de novo ATP1A3 variants as
      the primary cause of AHC.
  - reference: PMID:30891744
    reference_title: ATP1A3 mosaicism in families with alternating hemiplegia of childhood.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is the first systematic report of ATP1A3 mosaicism in AHC and showed mosaicism as an unrecognized source of previously considered \"de novo\" AHC. Identifying ATP1A3 mosaicism provides more evidence for estimating recurrence risk and has implications in genetic counseling of AHC."
    explanation: >-
      Parental mosaicism creates residual recurrence risk even when a variant
      initially appears de novo in a simplex AHC case.
prevalence:
- population: Pediatric patients
  percentage: Approximately 1 in 1,000,000
  notes: >-
    Published reviews consistently describe AHC as extremely rare, with
    estimates around 1 in 1,000,000 children.
  evidence:
  - reference: PMID:24821639
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Therefore the problems of misdiagnosis could account for the low prevalence of this syndrome."
    explanation: Supports the rarity estimate for pediatric AHC.
phenotypes:
- name: Episodic hemiplegia
  category: Neurologic
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    Recurrent transient hemiplegic attacks are the defining feature of AHC and
    may alternate sides or become bilateral.
  phenotype_term:
    preferred_term: episodic hemiplegia
    term:
      id: HP:0012194
      label: Episodic hemiplegia
  evidence:
  - reference: PMID:38043964
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alternating hemiplegia of childhood (AHC) is characterized by recurrent episodes of hemiplegia which may alternate sides between attacks."
    explanation: Directly supports the core paroxysmal hemiplegic phenotype.
- name: Global developmental delay
  category: Developmental
  frequency: FREQUENT
  description: >-
    Delayed motor, language, and cognitive development are common and may be
    persistent, especially in more severe ATP1A3-related disease.
  phenotype_term:
    preferred_term: global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:35945798
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "AHC is often associated with epileptic seizures and developmental delay."
    explanation: Supports developmental delay as a common non-paroxysmal feature.
- name: Dystonia
  category: Neurologic
  frequency: FREQUENT
  description: >-
    Paroxysmal dystonic posturing and tonic attacks are typical, sometimes
    accompanying hemiplegic spells.
  phenotype_term:
    preferred_term: dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:35945798
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alternating Hemiplegia of Childhood (AHC) is a rare disorder with onset in the first 18 months of life characterized by stereotyped paroxysmal manifestations of tonic and dystonic attacks, nystagmus with other oculomotor abnormalities, respiratory and autonomic dysfunctions."
    explanation: Supports dystonia as a typical paroxysmal manifestation.
- name: Nystagmus
  category: Neurologic
  frequency: FREQUENT
  description: >-
    Abnormal eye movements, particularly nystagmus, are common early clinical
    clues and may precede hemiplegic attacks.
  phenotype_term:
    preferred_term: nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: PMID:24821639
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the common earliest manifestations are dystonic or tonic attacks and nystagmus."
    explanation: Supports nystagmus as an early clue to AHC.
- name: Seizure
  category: Neurologic
  frequency: FREQUENT
  description: >-
    Epilepsy is common in AHC, can emerge early or later in the disease course,
    and is often drug resistant.
  phenotype_term:
    preferred_term: seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:31484714
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirty-two of 51 patients had epilepsy: 18 focal seizures, frontal more frequently than temporal, and then posterior."
    explanation: Supports seizure/epilepsy as a frequent AHC phenotype.
- name: Autonomic dysfunction
  category: Neurologic
  frequency: FREQUENT
  description: >-
    Respiratory and broader autonomic dysregulation are part of the classic
    paroxysmal AHC presentation.
  phenotype_term:
    preferred_term: Abnormality of the autonomic nervous system
    term:
      id: HP:0002270
      label: Abnormality of the autonomic nervous system
  evidence:
  - reference: PMID:35945798
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alternating Hemiplegia of Childhood (AHC) is a rare disorder with onset in the first 18 months of life characterized by stereotyped paroxysmal manifestations of tonic and dystonic attacks, nystagmus with other oculomotor abnormalities, respiratory and autonomic dysfunctions."
    explanation: Supports autonomic dysfunction as a core feature included in the attack phenotype.
- name: Ataxia
  category: Neurologic
  frequency: FREQUENT
  description: >-
    Ataxia is a common chronic motor manifestation that can persist between
    attacks.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:38043964
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "pervasive neurological disabilities (e.g., developmental delay, learning disabilities, choreoathetosis, and ataxia)."
    explanation: Supports ataxia as a chronic non-paroxysmal manifestation of AHC.
- name: Choreoathetosis
  category: Neurologic
  frequency: FREQUENT
  description: >-
    Choreoathetosis can persist between attacks as part of the chronic movement
    disorder phenotype.
  phenotype_term:
    preferred_term: Choreoathetosis
    term:
      id: HP:0001266
      label: Choreoathetosis
  evidence:
  - reference: PMID:38043964
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "pervasive neurological disabilities (e.g., developmental delay, learning disabilities, choreoathetosis, and ataxia)."
    explanation: Supports choreoathetosis as a chronic non-paroxysmal manifestation of AHC.
pathophysiology:
- name: ATP1A3-dependent neuronal membrane transport dysfunction
  description: >-
    Pathogenic ATP1A3 variants impair the neuronal alpha-3 subunit of the
    P-type sodium:potassium-exchanging transporter, weakening ATPase function
    and disrupting maintenance of transmembrane ionic gradients.
  gene:
    preferred_term: ATP1A3
    term:
      id: hgnc:801
      label: ATP1A3
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  molecular_functions:
  - preferred_term: P-type sodium:potassium-exchanging transporter activity
    term:
      id: GO:0005391
      label: P-type sodium:potassium-exchanging transporter activity
  biological_processes:
  - preferred_term: establishment or maintenance of transmembrane electrochemical gradient
    term:
      id: GO:0010248
      label: establishment or maintenance of transmembrane electrochemical gradient
    modifier: DYSREGULATED
  downstream:
  - target: Paroxysmal motor and oculomotor network instability
    description: Reduced Na+/K+-ATPase function destabilizes neuronal firing in attack-generating circuits.
  - target: Epileptogenic cortical network dysfunction
    description: Disrupted ionic homeostasis increases seizure susceptibility in a subset of patients.
  evidence:
  - reference: PMID:22842232
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "AHC-causing mutations in this gene caused consistent reductions in ATPase activity without affecting the level of protein expression."
    explanation: Directly supports ATP1A3 hypofunction as the molecular lesion in AHC.
  - reference: PMID:25996915
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in ATP1A3 cause Alternating Hemiplegia of Childhood (AHC) by disrupting function of the neuronal Na+/K+ ATPase."
    explanation: Supports the core ATP1A3 membrane-transport mechanism.
- name: Paroxysmal motor and oculomotor network instability
  description: >-
    ATP1A3 pump failure produces episodic instability in motor and oculomotor
    circuits, yielding hemiplegic attacks, dystonia, nystagmus, and autonomic
    spell clustering.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brainstem
    term:
      id: UBERON:0002298
      label: brainstem
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  biological_processes:
  - preferred_term: neuronal action potential
    term:
      id: GO:0019228
      label: neuronal action potential
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:35945798
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alternating Hemiplegia of Childhood (AHC) is a rare disorder with onset in the first 18 months of life characterized by stereotyped paroxysmal manifestations of tonic and dystonic attacks, nystagmus with other oculomotor abnormalities, respiratory and autonomic dysfunctions."
    explanation: Supports a paroxysmal motor and oculomotor circuit phenotype.
  - reference: PMID:24821639
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The variability of individual clinical presentations and evolution of symptoms have made diagnosis difficult."
    explanation: Supports variable paroxysmal presentations that reflect circuit-level instability.
  downstream:
  - target: Epileptogenic cortical network dysfunction
    description: Persistent circuit instability increases the chance of clinically overt epilepsy.
  - target: Chronic neurodevelopmental impairment
    description: Recurrent early attacks and ongoing dysfunction contribute to later persistent deficits.
- name: Epileptogenic cortical network dysfunction
  description: >-
    AHC can produce focal or generalized seizures, status epilepticus, and
    nonepileptic reduced-awareness spells that require EEG-based distinction.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  biological_processes:
  - preferred_term: neuronal action potential
    term:
      id: GO:0019228
      label: neuronal action potential
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:31484714
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirty-two of 51 patients had epilepsy: 18 focal seizures, frontal more frequently than temporal, and then posterior."
    explanation: Supports common epileptogenic involvement in AHC.
  - reference: PMID:31484714
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "EEG may become epileptiform only on follow-up."
    explanation: Supports the need for longitudinal EEG assessment when epilepsy is suspected.
  downstream:
  - target: Chronic neurodevelopmental impairment
    description: Recurrent epilepsy and status epilepticus can worsen persistent neurologic outcomes.
- name: Chronic neurodevelopmental impairment
  description: >-
    Recurrent attacks, epilepsy, and ATP1A3 dysfunction converge on persistent
    cognitive, motor, and behavioral disability.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  evidence:
  - reference: PMID:25996915
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with an E815K mutation demonstrate an earlier age of onset, more severe motor impairment and a higher prevalence of status epilepticus."
    explanation: Supports persistent severe neurologic impairment in a well-characterized AHC subgroup.
  - reference: PMID:36192182
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients had cognitive impairment."
    explanation: Supports chronic neurodevelopmental impairment across ATP1A3-related disease.
  - reference: PMID:35945798
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Some disorders caused by ATP1A3 variants have been defined as ATP1A3-related disorders"
    explanation: Supports overlap between AHC and broader ATP1A3-related neurodevelopmental disability.
genetic:
- name: ATP1A3
  gene_term:
    preferred_term: ATP1A3
    term:
      id: hgnc:801
      label: ATP1A3
  association: Causative
  notes: >-
    AHC is usually caused by de novo heterozygous ATP1A3 variants, with a small
    number of recurrent missense substitutions accounting for many cases.
  evidence:
  - reference: PMID:22842232
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This work identifies de novo ATP1A3 mutations as the primary cause of AHC"
    explanation: Supports ATP1A3 as the main causative gene and de novo mutation as the typical mode of occurrence.
  - reference: PMID:25996915
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of 143 simplex occurrences, 58 had D801N (40%), 38 had E815K(26%) and 11 had G947R (8%) mutations [corrected]."
    explanation: Supports the recurrent ATP1A3 variant spectrum in a large AHC cohort.
diagnosis:
- name: Clinical diagnosis using Aicardi criteria
  presence: >-
    Early-onset recurrent hemiplegic spells with sleep-related remission and
    associated dystonia/nystagmus remain the core clinical diagnostic pattern.
  description: >-
    AHC is diagnosed clinically from the characteristic attack pattern and
    neurologic course, then refined by genetic testing.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  evidence:
  - reference: PMID:38043964
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diagnosis is usually based on history and clinical grounds using the Aicardi criteria."
    explanation: Directly supports clinical diagnosis by history and criteria.
  - reference: PMID:24821639
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Age of onset is before 18 months and the common earliest manifestations are dystonic or tonic attacks and nystagmus."
    explanation: Supports the key clinical pattern used to recognize AHC.
- name: ATP1A3 molecular genetic testing
  presence: >-
    ATP1A3 sequencing confirms most typical cases and distinguishes AHC from
    mimicking episodic neurologic disorders.
  description: >-
    Sequencing of ATP1A3 is the key confirmatory diagnostic test in typical AHC,
    especially when attacks begin in infancy and are sleep-responsive.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  evidence:
  - reference: PMID:22842232
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This work identifies de novo ATP1A3 mutations as the primary cause of AHC"
    explanation: Supports ATP1A3 sequencing as the main confirmatory diagnostic test.
  - reference: PMID:25996915
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified ATP1A3 mutations by Sanger and whole genome sequencing"
    explanation: Supports sequencing-based confirmation in a large registry cohort.
- name: Electroencephalography to distinguish epileptic from nonepileptic spells
  presence: >-
    EEG helps separate epileptic seizures from reduced-awareness spells and may
    become abnormal only on follow-up.
  description: >-
    Video-EEG is useful when events could represent epilepsy, because some AHC
    spells are nonepileptic despite appearing seizure-like.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  evidence:
  - reference: PMID:31484714
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "captured RAS showed no concomitant EEG changes"
    explanation: Supports video-EEG as a discriminator between epileptic and nonepileptic events.
  - reference: PMID:31484714
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "EEG may become epileptiform only on follow-up."
    explanation: Supports follow-up EEG when the initial study is unrevealing.
- name: GeneReviews Diagnostic Baseline
  description: >-
    GeneReviews provides the authoritative diagnostic baseline within the ATP1A3-related disorder spectrum.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  evidence:
  - reference: PMID:20301294
    reference_title: "ATP1A3-Related Disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of ATP1A3-related disorder is established in a proband with suggestive findings and a heterozygous pathogenic variant in ATP1A3 identified by molecular genetic testing."
    explanation: >-
      GeneReviews defines the clinical-plus-molecular diagnostic criteria for ATP1A3-related disorders, which include alternating hemiplegia of childhood.
differential_diagnoses:
- name: Familial hemiplegic migraine
  disease_term:
    preferred_term: familial hemiplegic migraine
    term:
      id: MONDO:0000700
      label: familial hemiplegic migraine
  description: >-
    Familial hemiplegic migraine overlaps with AHC through episodic hemiplegia
    and ATP1A2/ATP1A3 involvement, but headache-predominant attacks and the
    broader infantile AHC phenotype favor FHM only when migraine features
    dominate.
  distinguishing_features:
  - Migraine aura and headache are more prominent in familial hemiplegic migraine.
  - AHC typically begins before 18 months and includes sleep-resolving, trigger-sensitive attacks with dystonia and nystagmus.
  evidence:
  - reference: PMID:22842232
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the clinical presentation of some of the family members with the ATP1A2 mutation was more consistent with familial hemiplegic migraine"
    explanation: Supports familial hemiplegic migraine as an important AHC mimic/overlap diagnosis.
- name: Epilepsy
  disease_term:
    preferred_term: epilepsy
    term:
      id: MONDO:0005027
      label: epilepsy
  description: >-
    AHC attacks may be mistaken for epilepsy, but video-EEG often shows that
    some spells are nonepileptic and that epileptiform abnormalities may appear
    only later.
  distinguishing_features:
  - Some AHC spells have no concomitant EEG change.
  - Hemiplegic attacks with sleep-related resolution and prominent dystonia point away from primary epilepsy.
  evidence:
  - reference: PMID:31484714
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epileptic seizures may be the first paroxysmal symptom."
    explanation: Supports epilepsy as a close clinical mimic during early presentation.
  - reference: PMID:31484714
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "captured RAS showed no concomitant EEG changes"
    explanation: Supports nonepileptic spell differentiation by video-EEG.
treatments:
- name: Flunarizine prophylaxis
  description: >-
    Flunarizine is the most commonly used preventive medication for reducing the
    frequency and intensity of paroxysmal events in AHC.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:38043964
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "flunarizine remains the treatment of choice."
    explanation: Supports flunarizine as the main preventive pharmacotherapy used in AHC.
  - reference: PMID:35945798
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Flunarizine is the most commonly used drug for reducing the frequency and intensity of paroxysmal events."
    explanation: Supports flunarizine as standard preventive therapy.
- name: Supportive trigger avoidance and sleep induction
  description: >-
    Trigger avoidance and rapid sleep induction are practical nonpharmacologic
    measures used to abort or reduce attacks.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:38043964
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Management of patients with AHC includes the rapid induction of sleep during paroxysmal attacks and the avoidance of identified triggers."
    explanation: Supports core supportive management for acute attacks.
- name: Antiseizure therapy
  description: >-
    Anti-seizure medication is used when epilepsy is present, although seizures
    are frequently drug resistant and may require escalation.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_phenotypes:
  - preferred_term: seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:31484714
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nineteen patients (59%) were drug resistant."
    explanation: Supports the need for seizure-directed therapy in AHC-associated epilepsy.
clinical_trials:
- name: NCT02408354
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Randomized crossover trial testing triheptanoin oil for ATP1A3-related AHC.
  evidence:
  - reference: clinicaltrials:NCT02408354
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of this project is to study the efficacy of triheptanoin oil in patients with Alternating Hemiplegia of Childhood (AHC) due to ATP1A3 gene mutation."
    explanation: Supports a disease-specific interventional trial in AHC.
- name: NCT06248645
  phase: PHASE_II
  status: RECRUITING
  description: >-
    Randomized crossover study of high-flow oxygen for acute dystonic and
    plegic attacks in ATP1A3-related AHC.
  evidence:
  - reference: clinicaltrials:NCT06248645
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The aim of the study is to assess the effect of high-flow oxygen administration (against placebo) as an acute treatment of dystonic and plegic attacks."
    explanation: Supports ongoing evaluation of an acute AHC attack treatment.
- name: NCT03857607
  phase: NOT_APPLICABLE
  status: UNKNOWN
  description: >-
    Observational natural-history study of ATP1A3-related disease in a UK-wide
    cohort.
  evidence:
  - reference: clinicaltrials:NCT03857607
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An observational study aiming to study the natural history of a UK-wide patient cohort with ATP1A3-related disease."
    explanation: Supports observational natural-history characterization of ATP1A3-related disease.
datasets:
- accession: PMID:25996915
  title: "Alternating Hemiplegia of Childhood: Retrospective Genetic Study and Genotype-Phenotype Correlations in 187 Subjects from the US AHCF Registry"
  description: >-
    Registry-derived human clinical cohort used for retrospective
    genotype-phenotype correlation and ATP1A3 mutation analysis in 187 AHC
    subjects.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: PHENOPACKETS
  sample_count: 187
  conditions:
  - US AHCF registry cohort
  - alternating hemiplegia of childhood
  publication: PMID:25996915
  evidence:
  - reference: PMID:25996915
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We performed mutation analysis and retrospective genotype-phenotype correlations in all eligible patients with AHC enrolled in the US AHC Foundation registry from 1997-2012."
    explanation: Directly supports the registry cohort as a curated AHC dataset.
notes: >-
  Asta deep research was completed and used to seed this curation. The entry
  prioritizes primary human clinical literature, a large registry cohort, and
  current clinical trial records for AHC.
references:
- reference: PMID:20301294
  title: "ATP1A3-Related Disorder."
  tags:
  - GeneReviews
  findings: []
- reference: url:https://www.ncbi.nlm.nih.gov/books/NBK1115/
  title: "ATP1A3-Related Disorder - GeneReviews - NCBI Bookshelf"
  tags:
  - GeneReviews
  findings: []
- reference: PMID:30891744
  title: ATP1A3 mosaicism in families with alternating hemiplegia of childhood.
  findings: []
📚

References & Deep Research

References

3
ATP1A3-Related Disorder.
No top-level findings curated for this source.
ATP1A3-Related Disorder - GeneReviews - NCBI Bookshelf
No top-level findings curated for this source.
ATP1A3 mosaicism in families with alternating hemiplegia of childhood.
No top-level findings curated for this source.

Deep Research

1
Asta
Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Alternating Hemiplegia of Childhood. Core disease mechanisms, molecular an...
Asta Scientific Corpus Retrieval 17 citations 2026-04-16T14:53:59.050901

Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Alternating Hemiplegia of Childhood. Core disease mechanisms, molecular an...

This report is retrieval-only and is generated directly from Asta results.

  • Papers retrieved: 17
  • Snippets retrieved: 20

Relevant Papers

[1] Advances for pediatricians in 2022: allergy, anesthesiology, cardiology, dermatology, endocrinology, gastroenterology, genetics, global health, infectious diseases, metabolism, neonatology, neurology, oncology, pulmonology

  • Authors: C. Caffarelli, Francesca Santamaria, E. Piro, S. Basilicata, Lorenzo D'Antonio et al.
  • Year: 2023
  • Venue: Italian Journal of Pediatrics
  • URL: https://www.semanticscholar.org/paper/11322879fbcc4194d6764fd92a408e1c2b1d9840
  • DOI: 10.1186/s13052-023-01522-8
  • PMID: 37679850
  • PMCID: 10485969
  • Citations: 1
  • Summary: Novel valuable developments in epidemiology, pathophysiology, prevention, diagnosis and treatment that can rapidly change the approach to diseases in childhood have been included and discussed.
  • Evidence snippets:
  • Snippet 1 (score: 0.505) > Alternating hemiplegia of childhood is an uncommon complex disorder, which was first described in late 1960s by Verret and Steele [160]. Alternating hemiplegia of childhood is characterized by paroxysmal episodes of repeated, transient paresis involving either or both sides of the body and usually presents before age 18 months. The diagnosis of alternating hemiplegia of childhood is mainly clinical but may be supported by molecular analysis. Although the pathophysiologic mechanism of the disorder is partially unclear, it is well known that a relevant role is played by mutations in ATP1A2 and ATP1A3 genes, which encode two different alpha subunits of the Na+/K + ATPase transmembrane ion pump, respectively [161]. Pavone et al. [162] reported on the clinical and genetic findings of a couple of twins and a couple of siblings with alternating hemiplegia of childhood from two different Italian families affected. In the twins a pathogenic variant in ATP1A3 gene (c.2318 A > G) was detected. In the siblings, the younger brother showed a novel GRIN2A variant (c.3175 T > A), while the older one carried the same GRIN2A variant, associated with two likely pathogenetic variants in SCNIB (c.632 > A) and KCNQ2 (1870 G > A) genes, which have been implicated in childhood epilepsies. This report provides additional information about alternating hemiplegia of childhood, showing that the variability of clinical features is mirrored by an unexpected genetic heterogeneity. Clinical signs of alternating hemiplegia of childhood usually follow a sequential pattern, in which the paroxysmal episodes are triggered by precipitating factors such as environmental stress, bathing or other events. Non-paroxysmal features include developmental delay/ intellectual disability, epilepsy, autonomic dysfunctions, abnormal eye involvement, movement disorders, ataxia, dystonia, and choreoathetosis [163].

[2] Alternating hemiplegia of childhood: a distinct clinical entity and ATP1A3-related disorders: A narrative review

  • Authors: P. Pavone, X. Pappalardo, M. Ruggieri, R. Falsaperla, E. Parano
  • Year: 2022
  • Venue: Medicine
  • URL: https://www.semanticscholar.org/paper/66be2e43c32ba1ed3e66fd144bf09ce7e8632a40
  • DOI: 10.1097/MD.0000000000029413
  • PMID: 35945798
  • PMCID: 9351909
  • Citations: 11
  • Summary: Historical annotations of AHC, symptoms, signs and associated morbidities, diagnosis and differential diagnosis, treatment, prognosis, and genetics are discussed.
  • Evidence snippets:
  • Snippet 1 (score: 0.498) > Alternating hemiplegia of childhood (AHC) is an uncommon neurological disorder mainly characterized by paroxysmal transient events of paresis involving either or both sides of the body, usually before the age of 18 months. [1,2] Events are often preceded by precipitating factors such as environmental stress, bathing, and psychological factors. Paroxysmal episodes may occur independently or in association with other clinical manifestations, such as autonomic Medicine dysfunction, altered awareness, and abnormal movements, such as dystonia, ataxia, and choreoathetosis. Affected individuals may show developmental delay/intellectual disability (DD/ID) and epileptic seizures. [1][2][3][4] Some symptoms tend to occur in sequential distinctive phases and disappear with sleep. [1][2][3][4] The prevalence of AHC is 1/1,000,000 in children under the age of 16 years, but this number could be underestimated due to the variability in clinical presentation and the lack of genetic analysis in the preceding epidemiologic data. [5,6] The underlying pathophysiological mechanisms of AHC and/or the various complex co-morbidities are not completely known. Advanced molecular research has allowed a better understanding of causal genes involved and provides, at the same time, early confirmation of the diagnosis. Mutations in ATP1A2 (AHC1; OMIM#104290) and ATP1A3 (AHC2; OMIM#614820), which encode two different alpha subunits of the neuronal NA+-K+ ATPase transmembrane ion pump, are the most frequent involved genes. [7][8][9][10] AHC individuals with ATP1A3 mutations are numerically more common than those with ATP1A2 mutations. [11] The wider use of genetic technology has enabled it to differentiate AHC diagnosis from other similar disorders and to extend its clinical spectrum. The aim of this study was not only to review the most recent clinical features and genetic data of the AHC disorder with its distinctive clinical and comorbidity variability but especially to report on other conditions linked to ATP1A3 mutations: ATP1A3-related disorders and ATP

[3] Navigating the Complexity of Alternating Hemiplegia in Childhood: A Comprehensive Review

  • Authors: J. Rissardo, Nilorfar Murtaza Vora, Yogendra Singh, S. Kishore, A. Caprara
  • Year: 2024
  • Venue: Rambam Maimonides Medical Journal
  • URL: https://www.semanticscholar.org/paper/08e057b637af02f8cf013b32e89d9dc607e9b03c
  • DOI: 10.5041/RMMJ.10529
  • PMID: 39088707
  • PMCID: 11294682
  • Citations: 2
  • Summary: New diagnostic criteria for AHC is proposed, dividing it into clinical, laboratory, supporting, and atypical features, and the location of the mutations in the ATP1A3 protein of individuals with AHC, rapid-onset dystonia-parkinsonism (RDP) variants, and early infantile epileptic encephalopathy (variants with hemiplegic attack).
  • Evidence snippets:
  • Snippet 1 (score: 0.490) > Alternating hemiplegia of childhood (AHC) is a complex neurodevelopmental disorder mainly characterized by paroxysmal transient events of unilateral or bilateral paresis, usually before 18 months. 1 It is a rare and severe neurological disorder with a prevalence of 1:100,000 to 1:1,000,000. 2 Little is known about the several genetic, environmental, and biological factors that could potentially contribute to the pathophysiology of AHC. In this way, diagnosis and management are empirical in many cases, with few evidence-based studies to support specific tests or therapeutic strategies. > The AHC disorder has been associated with mutations in the ATP1A3 gene, which encodes the alpha-3 subunit of the neuronal Na + /K + -ATPase transmembrane ion pump in approximately 75% of patients. 3 The ATP1A3 gene is highly expressed in brain regions that influence the autonomic nervous system. 4 In approximately a quarter of the patients, ATP1A2 mutations were encountered, while in a minority of the subjects, the etiology is still unknown. > The presentation of AHC is often associated with precipitating factors such as environmental and psychological stressors. Paroxysmal episodes may occur independently or in association with other clinical manifestations, such as autonomic dysfunction, altered mental status, and abnormal movements, such as dystonia, ataxia, and choreoathetosis. 5 typical clinical pattern can be observed in most individuals with AHC. In this way, it is possible to divide the clinical progression of the disease into three phases. The first phase occurs during the first 3 months of age, and the main clinical feature is abnormal ocular movements, which can be associated with dystonia. 1 The second phase generally starts at 4 months and usually extends until 6 years; it is characterized by hemiplegic spells. In this phase, the patient can also present delayed developmental milestones and seizures. 5 In the last phase, unremitting neurological deficits could be observed. Other significant findings in the last phase include persistent developmental delays and, less frequently, hemiplegic and dystonic spells.
  • Snippet 2 (score: 0.410) > Alternating hemiplegia of childhood is a complex and diverse disorder characterized primarily by hemiplegic episodes, varying widely in frequency and intensity. These episodes commonly coincide with epilepsy, developmental delay, movement disorders, and autonomic nervous system dysfunction. Most AHC cases are associated with ATP1A3-related disorders, encompassing RDP, CAPOS syndrome, EIEE, childhood rapid-onset ataxia, and relapsing encephalopathy with cerebellar ataxia.

[4] Alternating hemiplegia of childhood: new diagnostic options.

  • Authors: A. Gergont, M. Kaciński
  • Year: 2014
  • Venue: Neurologia i neurochirurgia polska
  • URL: https://www.semanticscholar.org/paper/713528dee2a22d6a5e55652cd7ff24fea78e1f36
  • DOI: 10.1016/j.pjnns.2013.05.003
  • PMID: 24821639
  • Citations: 14
  • Summary: The variability of individual clinical presentations and evolution of symptoms have made diagnosis difficult, and the problems of misdiagnosis could account for the low prevalence of this syndrome.
  • Evidence snippets:
  • Snippet 1 (score: 0.457) > in 1976 as 'alternating hemiplegia in a child' [8]. The next case of a girl with AHC hospitalized at the Department of Neurology of Polish Mother's Memorial Research Institute Hospital (Centrum Zdrowia Matki Polki) in Łodź was described in 1995 as 'alternating hemiplegia' [9]. The term 'alternating hemiplegia of childhood' was applied in the paper related to the significance of neuronal channelopathies in the pathogenesis of migraine [10].
  • Snippet 2 (score: 0.423) > Alternating hemiplegia of childhood (AHC, MIM 104290) was presented by Verret and Steel in 1971 [1]. Alternating hemiplegia of childhood is a rare syndrome with an early manifestation, and its diagnosis is based on the clinical symptoms fulfilling the criteria. The incidence has been estimated at 1 in 1000,000 births but the underestimation of the burden of AHC could be suspected due to the lack of sufficient knowledge about this syndrome or lack of diagnostic laboratory or radiological test confirming diagnosis with certainty [2]. Until recently, no hypothesis explaining AHC pathomechanism has been confirmed. Although in single cases pathological changes were detected suggesting vasculitis or mitochondrial enzymatic chain disorders, specific marker of the disease was not defined. The phenotypic features common with migraine (hemiplegia as a symptom of motor migraine aura) suggested that AHC constitutes migraine precursor or variant of hemiplegic migraine (FHM, familial hemiplegic migraine). Majority of presented cases were predominantly sporadic, however familial cases with transmission suggesting autosomal dominant trait were presented [3,4]. > Multicenter research on AHC pathomechanism succeeded with the identification of ATP1A3 mutation. The research was conducted in collaboration with European Network for Research on Alternating Hemiplegia (ENRAH), an organization including patients and their families as well as clinicians to help coordinate epidemiological data and to promote research efforts [5,6]. > The translation of the name of the syndrome into Polish was not unified. In the publication of the Polish version of the International Classification of Headache Disorders 'alternating plegia of childhood' (naprzemienne porażenie dziecięce) was presented in a section of childhood periodic syndromes that are commonly precursors of migraine [7]. A case of a patient hospitalized at the Department of Developmental Neurology AM in Gdańsk was presented in 1976 as 'alternating hemiplegia in a child' [8]. The next case of a girl with AHC hospitalized at the Department of Neurology of Polish Mother's Memorial Research Institute Hospital (Centrum Zdrowia Matki Polki) in Łodź was described in 1995 as 'alternating

[5] Alternating hemiplegia of childhood and rapid-onset dystonia-parkinsonism are both ATP1A3-related disorders

  • Authors: H. Rosewich, H. Thiele, A. Ohlenbusch, U. Maschke, P. Frommolt et al.
  • Year: 2014
  • Venue: Molecular and Cellular Pediatrics
  • URL: https://www.semanticscholar.org/paper/1df28fb6e33b5935288ec8ee50937f875ab71285
  • DOI: 10.1186/2194-7791-1-S1-A15
  • PMCID: 4715209
  • Summary: This study showed that AHC and RDP are not two distinct diseases but rather constitute a clinical continuum of one disorder with AHC at the severe end of the spectrum and R DP as a milder variant.
  • Evidence snippets:
  • Snippet 1 (score: 0.450) > Alternating hemiplegia of childhood (AHC) was first described as a distinctive disease in 1971 [1]. The disease is characterised by early-onset episodes of hemiplegia, dystonia, numerous paroxysmal symptoms, and developmental impairment [2]. Almost all cases of AHC are sporadic. > To identify de-novo mutations associated with this disease 40 clinically well-characterized patients were recruited from September 2004 till April 2013. Whole-exome sequencing was performed in three proband-parent trios. Informative genes were evaluated in the 37 remaining patients and ATP1A3 emerged as the gene associated with AHC [3]. Interestingly, this gene was already known to be associated with another movement disorder with later onset namely rapid-onset dystonia-parkinsonism (RDP) [4]. We then thoroughly analysed clinical and molecular findings of AHC and RDP to evaluate the phenotypic and genotypic spectrum. In addition, we started to analyse the functional consequences of the encoded Na+,K+ alpha 3 subunit for different ATP1A3 mutations associated with either AHC or RDP applying cell survival assays and two-electrode voltage clamp techniques. > 39 of 40 patients with a characteristic AHC/RDP phenotype displayed a de-novo mutation in ATP1A3. Our study first showed that AHC and RDP are not two distinct diseases but rather constitute a clinical continuum of one disorder with AHC at the severe end of the spectrum and RDP as a milder variant. Clinically overlapping features are abrupt onset of triggered dystonic episodes, a rostrocaudal gradient of involvement as well as brainstem dysfunction; clearly differentiating characteristics are fixed dystonia in RDP and episodic hemiplegia in AHC. Further, mutations affecting functional and transmembrane protein domains tend to be associated with an AHC phenotype and the majority of ATP1A3 mutations are located in only four exons [5]. To further elucidate the pathomechanisms of ATP1A3 related disorders in vitro studies on selected mutations are ongoing.

[6] Alternating Hemiplegia

  • Authors: Unknown authors
  • Year: 2019
  • Venue: Definitions
  • URL: https://www.semanticscholar.org/paper/7b2552d203bf4701f5aef7b5c6b23c617bf1280a
  • DOI: 10.32388/379185
  • Citations: 2
  • Summary: Alternating hemiplegia is a rare neurological disorder that develops in childhood, most often before the child is 18 months old. T he disorder is characterized by recurrent episodes of paralysis that involve one or both sides of the body, multiple limbs, or a single limb. T he paralysis may affect different parts of the body at different times and may be brief or last for several days. Oftentimes these episodes will resolve after sleep. Affected children may also have abnormal movements invol...
  • Evidence snippets:
  • Snippet 1 (score: 0.448) > Alternating hemiplegia is a rare neurological disorder that develops in childhood, most often before the child is 18 months old. T he disorder is characterized by recurrent episodes of paralysis that involve one or both sides of the body, multiple limbs, or a single limb. T he paralysis may affect different parts of the body at different times and may be brief or last for several days. Oftentimes these episodes will resolve after sleep. Affected children may also have abnormal movements involving stiffening or "dance-like" movements of a limb, as well as walking and balance problems. Some children have seizures. Children may have normal or delayed development. T here are both benign and more serious forms of the disorder. Alternating hemiplegia is primarily caused by mutations in the AT P1A3 gene. Occasionally, a mutation in the AT P1A2 gene is involved in the condition. T hese genes provide instructions for making very similar proteins. Mutations in these genes reduce the activity of an enzyme called Na+/K+ AT Pase, which affects the signals that control muscle movement. However, it not yet clear how the reduced enzyme activity leads to the symptoms of the disorder. Qeios · Definition, November 11, 2019

[7] Molecular genetic and mitochondrial metabolic analyses confirm the suspected mitochondrial etiology in a pediatric patient with an atypical form of alternating hemiplegia of childhood

  • Authors: A. Gropman, M. Uittenbogaard, C. Brantner, Yue Wang, L. Wong et al.
  • Year: 2020
  • Venue: Molecular Genetics and Metabolism Reports
  • URL: https://www.semanticscholar.org/paper/7b19702f1dff967d80ee93e4781d45d75f256bfa
  • DOI: 10.1016/j.ymgmr.2020.100609
  • PMID: 32489883
  • PMCID: 7262444
  • Citations: 9
  • Summary: Comprehensive genetic and metabolic analyses suggest an oligogenic inheritance among the nuclear and mitochondrial variants for the mitochondrial etiology of proband's atypical form of AHC, thereby providing critical insight in terms of genetic clues and bioenergetic deficit.
  • Evidence snippets:
  • Snippet 1 (score: 0.448) > The rare neurodevelopmental disorder, alternating hemiplegia of childhood (AHC) (OMIM 614820), originally described by Verret and Steele in 1971 [1], is characterized by an extensive phenotypic variability. Thus, its clinical diagnosis is challenging, but facilitated by the Aicardi criteria [2]: 1) onset before the age of 18 months; 2) recurrent transient attacks of hemiplegia involving either side; 3) paroxysmal involuntary movements, such as nystagmus, tonic attacks, dystonic posturing, choreoathetosis, and autonomic abnormalities; 4) progressive neurological deficits, such as speech disorder, behavioral deficits, cognitive impairment, and developmental delay. Our understanding of the pathophysiological mechanisms of AHC remains limited, thereby hindering the development of effective therapeutic options. > The advent of next-generation sequencing led to the discovery of the first pathogenic clue of AHC, revealing that AHC is a predominantly sporadic disorder [3]. About 75% of AHC patients harbor a de novo heterozygous mutation in the ATP1A3 gene encoding the alpha 3 subunit of the neuronal Na + /K + ATPase protein involved in the regulation of neuronal excitability [4][5][6]. Mutations in the ATP1A2 gene encoding for the alpha 2 subunit of the Na + /K + ATPase protein also cause a very small number of AHC cases (OMIM 104290) [7][8][9]. Thus, additional causative genes remain to be identified, resulting in patients clinically diagnosed with AHC of unknown etiology and molecular genetic diagnosis. Several studies have evoked a mitochondrial etiology in a few https://doi.org/10.1016/j.ymgmr.2020.100609 Received 21 May 2020; Accepted 21 May 2020 patients with AHC. Mitochondrial abnormalities have been observed by 31 P magnetic resonance spectroscopy in skeletal muscle [10], while abnormal enzyme activities of the mitochondrial oxidative phosphorylation (OXPHOS) pathway were detected in skin biopsies from a handful of AHC patients [11,12].

[8] De novo mutations in ATP1A3 cause alternating hemiplegia of childhood

  • Authors: E. Heinzen, K. Swoboda, Y. Hitomi, F. Gurrieri, S. Nicole et al.
  • Year: 2012
  • Venue: Nature genetics
  • URL: https://www.semanticscholar.org/paper/74faf2f2bb39510b57e36559dc960c624079096f
  • DOI: 10.1038/ng.2358
  • PMID: 22842232
  • PMCID: 3442240
  • Citations: 383
  • Influential citations: 16
  • Summary: De novo ATP1A3 mutations are identified as the primary cause ofAlternating hemiplegia of childhood and insight into disease pathophysiology is offered by expanding the spectrum of phenotypes associated with mutations in ATP 1A3.
  • Evidence snippets:
  • Snippet 1 (score: 0.444) > Alternating hemiplegia of childhood (AHC) is a rare, severe neurodevelopmental syndrome characterized by recurrent hemiplegic episodes and distinct neurological manifestations. AHC is usually a sporadic disorder and has unknown etiology. We used exome sequencing of seven patients with AHC and their unaffected parents to identify de novo nonsynonymous mutations in ATP1A3 in all seven individuals. In a subsequent sequence analysis of ATP1A3 in 98 other patients with AHC, we found that ATP1A3 mutations were likely to be responsible for at least 74% of the cases; we also identified one inherited mutation in a case of familial AHC. Notably, most AHC cases are caused by one of seven recurrent ATP1A3 mutations, one of which was observed in 36 patients. Unlike ATP1A3 mutations that cause rapid-onset dystonia-parkinsonism, AHC-causing mutations in this gene caused consistent reductions in ATPase activity without affecting the level of protein expression. This work identifies de novo ATP1A3 mutations as the primary cause of AHC and offers insight into disease pathophysiology by expanding the spectrum of phenotypes associated with mutations in ATP1A3.

[9] Alternating Hemiplegia of Childhood Caused by ATP1A3 Mutations: A Report of Two Cases.

  • Authors: Guanzhao Yang, Z. Zhao, Yang Yang, Li Lin, Conglei Song et al.
  • Year: 2021
  • Venue: Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • URL: https://www.semanticscholar.org/paper/63b53d21f673ec159fddd8a29c3649247ebbd103
  • DOI: 10.24920/003850
  • PMID: 34231463
  • Citations: 4
  • Summary: Funarizine can significantly improve the paroxysmal motor symptoms of pediatric patients with alternating hemiplegia and carry heterozygous missense mutations in theATP1A3 gene.
  • Evidence snippets:
  • Snippet 1 (score: 0.440) > Alternating Hemiplegia of Childhood Caused by ATP1A3 Mutations: A Report of Two Cases.

[10] Alternating Hemiplegia of Childhood with ATP1A3 Gene Mutation- A Case Report

  • Authors: R. Islam, K. Fatema, M. Rahman
  • Year: 2022
  • Venue: Bangladesh Journal of Child Health
  • URL: https://www.semanticscholar.org/paper/2d32d1969b834ff7ef78c1d2c23268c3655ae7d1
  • DOI: 10.3329/bjch.v45i3.62896
  • Summary: The case of 8.5 year old girl with AHC who had a heterozygous de-novo p.Leu839Pro (c.2516T>C) pathogenic mutation of ATP1A3 gene on chromosome 19q13 is presented.
  • Evidence snippets:
  • Snippet 1 (score: 0.435) > Alternating Hemiplegia of Childhood with ATP1A3 Gene Mutation- A Case Report

[11] Alternating Hemiplegia of Childhood: Retrospective Genetic Study and Genotype-Phenotype Correlations in 187 Subjects from the US AHCF Registry

  • Authors: L. Viollet, Gwênlyn Glusman, Kelley J. Murphy, T. Newcomb, S. Reyna et al.
  • Year: 2015
  • Venue: PLoS ONE
  • URL: https://www.semanticscholar.org/paper/d8182c5129a2b47e26b6f9cbe86e51235c65a300
  • DOI: 10.1371/journal.pone.0127045
  • PMID: 25996915
  • PMCID: 4440742
  • Citations: 72
  • Influential citations: 5
  • Summary: A more deleterious effect of the E815K mutation on selected neurologic outcomes is confirmed and the complexity of the disorder and the extensive phenotypic variability among subgroups merits caution and emphasizes the need for further studies.
  • Evidence snippets:
  • Snippet 1 (score: 0.435) > Alternating Hemiplegia of Childhood (AHC, MIM#614820) is a rare and complex neurodevelopmental disorder described initially by Verret and Steele in 1971, and named for the characteristic recurrent attacks of hemiplegia that affected first one side of the body, then another.However, episodes of paroxysmal neurologic dysfunction in this unusual disorder encompass a wide range of abnormal movements and episode types ranging from hemiplegia to quadriplegia to dystonia, and lasting from minutes to hours or even days.A variety of external or emotional stressors trigger the onset or worsening of paroxysmal symptoms, but they are consistently relieved by sleep, whether pharmacologically or naturally induced [1,2].Although rare familial cases with autosomal dominant inheritance have been reported [3][4][5][6], AHC is predominantly a sporadic disorder.Estimated incidence of the classic form of the disease is 1 in one million: males and females are affected in roughly equal numbers.The variability and the complexity of presenting symptoms have historically led to considerable delays in diagnosis, which was until recently based solely on carefully conceived clinical diagnostic criteria.These criteria specified an infantile onset (< 18 months) of recurrent paroxysmal episodes of hemiplegia, dystonia and ocular movement abnormalities, and were ultimately characterized by the appearance of additional fixed neurologic signs and symptoms including chorea, dysarthria, dyskinesia, ocular apraxia, ataxia and global developmental delay [2,7,8].The variable course of the disease and limited longitudinal follow-up and neuropathologic data have led to ongoing speculation as to whether or not AHC represents a static neurodevelopmental or a progressive disorder [9][10][11]. > The pathophysiology of AHC was totally unknown until the recent identification of mutations in ATP1A3, which encodes a neuron specific sodium/potassium ATPase involved in the regulation of neuronal excitability [12].We and others initially identified de novo recurrent mutations in ATP1A3 by performing whole exome studies in trios in a series of simplex AHC patients.

[12] A case of alternating hemiplegia in 2-month-old children with nystagmus as the first symptom: A case report

  • Authors: Qicheng Qiao, Qiubo Li
  • Year: 2024
  • Venue: Medicine
  • URL: https://www.semanticscholar.org/paper/02b1132b61c337ee1f8abf2a4660f480a9a58c2e
  • DOI: 10.1097/MD.0000000000039774
  • PMID: 39331927
  • PMCID: 11441957
  • Summary: A case of a 2-month-old child with nystagmus as the initial symptom, followed by limb movement disorder in the left upper limb and weakness in the right limbs diagnosed with alternating hemiplegia of childhood, underscores the importance of early recognition and prompt intervention in managing children with AHC.
  • Evidence snippets:
  • Snippet 1 (score: 0.431) > Alternating hemiplegia of childhood (AHC) is a rare neurological condition that typically presents in infants under the age of 18 months with intermittent episodes of hemiplegia, affecting one or both sides of the body. These episodes are often triggered by stressors such as environmental changes, bathing, or emotional stress. They can manifest alone or alongside other symptoms including autonomic instability, altered consciousness, and movement disorders, such as dystonia, ataxia, and choreoathetosis. Patients may also develop developmental or intellectual disabilities and experience epileptic seizures. Notably, certain symptoms appear in distinct phases and typically resolve during sleep. The incidence of AHC is estimated at 1 in 1,000,000 among children under the age of 16 years, a figure that may underrepresent the true prevalence due to the Qiao and Li • Medicine (2024) Medicine condition's diverse clinical presentations and the limited genetic testing in past studies. [1,2] The precise pathophysiology of AHC, including its associated comorbidities, remains incompletely understood. However, recent advances in molecular genetics have led to a clearer understanding of the genes implicated in AHC, facilitating earlier and more definitive diagnoses. The most commonly associated genes are mutations in ATP1A2 and ATP1A3, which are responsible for producing different alpha subunits of the neuronal Na+-K + ATPase pump. Individuals with ATP1A3 mutations are more frequently affected than those with ATP1A2 mutations. The increased application of genetic testing has not only improved the differentiation of AHC from other similar disorders but also expanded the recognized clinical spectrum of the condition. This article reports a case of alternating hemiplegia in children with nystagmus as the first symptom.

[13] Alternating Hemiplegia of Childhood: neurological comorbidities and intrafamilial variability

  • Authors: P. Pavone, X. Pappalardo, Naira M Mustafa, S. Cho, D. Jin et al.
  • Year: 2022
  • Venue: Italian Journal of Pediatrics
  • URL: https://www.semanticscholar.org/paper/bd96c802f4dee91e3cddeb3b66267225cf30a3f2
  • DOI: 10.1186/s13052-021-01194-2
  • PMID: 35177115
  • PMCID: 8851838
  • Citations: 6
  • Summary: Clinical features of AHC may be also the result of an unexpected genetic heterogeneity and neurological co-morbidities are various and frequently reported including developmental delay, epilepsy, tonic or dystonic spells, nystagmus,autonomic manifestations with intrafamilial variability.
  • Evidence snippets:
  • Snippet 1 (score: 0.427) > Alternating Hemiplegia of Childhood (AHC) is an uncommon complex disorder, mainly characterized by paroxysmal episodes of repeated, transient paresis involving either or both sides of the body with onset usually before the age of 18 months. This disorder was first described in late 1960s by Verret and Steele on their study, which included eight children with migraine, among whom three showed the characteristic features of AHC [1]. Diagnostic criteria for AHC were expressed by Krageloh and Aicardi [2] and Bourgeois et al. [3] and consist of: a) onset before the age of 18-months; b) autonomic phenomena; c) cognitive impairment; d) repeated episodes of hemiplegia that sometimes involve both sides of the body; e) neurological abnormalities such as choreoathetosis; f) disappearance of the symptoms with the sleep and their resume after waking. The clinical signs of AHC are complex, heterogeneous, and follow a unique pattern: their clinical progression tends to occur in sequential distinctive phases, the paroxysmal episodes are often preceded by precipitating factors such as environmental stress, bathing and other events [4]. Nonparoxysmal features of subjects with AHC are various and include developmental delay/intellectual disability (DD/ID), epilepsy, autonomic dysfunctions, abnormal eye involvement, movement disorders, ataxia, dystonia, and choreoathetosis [4][5][6][7][8]. > Although the pathophysiologic mechanism causing the clinical expression of the disorder remain unknown, significant research advances over the years, particularly those seen in the clinical genetics field, allowed a better mechanistic understanding of the attributed genes and enabled early diagnosis and precocious treatment. Relevant etiopathogenetic role in AHC is linked to mutations in ATP1A2 (AHC-1; OMIM#104290) and in ATP1A3 genes (AHC-2; OMIM#614820), respectively which encode two different alpha subunits of the Na + /K + ATPase transmembrane ion pump [9,10]. ATP1A3 is by far more common than ATP1A2 mutation [11]. It is worth mentioning

[14] Alternating Hemiplegia of Childhood and Neurological Comorbidities. Variable Intrafamilial Clinical Features.

  • Authors: P. Pavone, X. Pappalardo, Naira M Mustafa, S. Cho, D. Jin et al.
  • Year: 2020
  • Venue: Unknown venue
  • URL: https://www.semanticscholar.org/paper/76a5e6e02442e2a646cb88082b78d11e25b270ac
  • DOI: 10.21203/rs.3.rs-73126/v1
  • Summary: The view of the disorder should be greatly changed to the term “AHC spectrum disorder" due to how the genetic framework is not recurrent, but may result from an unexpected greater genetic heterogeneity, such as seen in siblings carrying a new set of gene variants implicated in channelopathies likely to be eligible as further risk factors for AHC.
  • Evidence snippets:
  • Snippet 1 (score: 0.423) > Alternating Hemiplegia of Childhood (AHC) is an uncommon complex disorder, characterized mainly by paroxysmal episodes of repeated, transient paresis involving either or both sides of the body with onset usually before the age of 18 months. Subjects with AHC also present with non-paroxysmal features including Developmental Delay/Intellectual Disability (DD/ID), epileptic seizures, autonomic dysfunction, abnormal eye movements, motor impairment, ataxia, dystonia and movement disorders such as choreoathetosis [1][2][3] .This disorder was rst described in late 1960s by Verret and Steele on their study, which included eight children with migraine, among whom three showed the characteristic features of AHC [1]. > Although the pathophysiologic mechanisms causing the clinical expression of the disorder remain unknown, signi cant research advances over the years, particularly those seen in the clinical genetics eld, allowed for a better mechanistic understanding of the attributed genes and enabled early diagnosis and effective treatment. Two types of AHC have been described; AHC-1 (OMIM#104290) and AHC-2 (OMIM#614820), characterized by mutations in ATP1A2 and ATP1A3 genes respectively, which encode two different alpha subunits of the Na + /K + ATPase transmembrane ion pump [4,5]. ATP1A3 is by far more common than ATP1A2 mutation [6]. It is worth mentioning that clinical expression of ATP1A3 mutations are expanding and includes the complex disorders ATP1A3-related [7]. The rise and widespread implementation of the whole exome sequencing (WES) technology has notably enhanced the gene mutation panel analyzing additional genes clinically-overlapped with the AHC spectrum. It is essential to highlight that AHC as observed in the literature is a complex disorder in which the paroxysmal hemiplegia is only one feature, even if the most relevant, among several other clinical manifestations each of which is considered as a primary component of this disorder. Consequently, we agree that the extensive term "AHC spectrum disorder" may be correctly applied.

[15] Alternating Hemiplegia of Childhood: Genotype–Phenotype Correlations in a Cohort of 39 Italian Patients

  • Authors: R. Cordani, M. Stagnaro, L. Pisciotta, F. Tiziano, M. Calevo et al.
  • Year: 2021
  • Venue: Frontiers in Neurology
  • URL: https://www.semanticscholar.org/paper/9faa9248277ffe749885faf4b1619ad2189b909c
  • DOI: 10.3389/fneur.2021.658451
  • PMID: 33897609
  • PMCID: 8060701
  • Citations: 22
  • Influential citations: 1
  • Summary: The research suggests a genotype–phenotype correlation and provides information on this disorder's features, clinical course, and treatment.
  • Evidence snippets:
  • Snippet 1 (score: 0.423) > Alternating Hemiplegia of Childhood (AHC) (OMIM #614820) is a rare and peculiar neurologic disorder, first described in 1971 (1). The annual incidence is < 1/100,000 newborns (2). In AHC, a complex phenotype combines paroxysmal non-epileptic episodes, often triggered by contact with water, changes in temperature, physical or psychological stress, and epileptic seizures, both focal and generalized, with a high rate of refractory/super refractory status epilepticus (3). Developmental issues, cognitive deficits, neuropsychological impairments, and persistent neurologic disorders (2,(4)(5)(6) are expected hallmarks. In 1993, specific diagnostic criteria for AHC were first introduced (7) and then periodically updated. Aicardi's criteria for AHC (8) are (1) onset of paroxysmal events before 18 months of age; (2) repeated bouts of hemiplegia involving the right and left sides of the body during some attacks; (3) episodes of bilateral hemiplegia or quadriplegia starting either as a generalization of a hemiplegic episode or as bilateral from the start; (4) other paroxysmal disturbances including tonic/dystonic attacks, nystagmus, strabismus, dyspnea, and other autonomic phenomena occurring during hemiplegic bouts or in isolation; (5) immediate disappearance of all symptoms upon sleep, with probable recurrence of long-lasting bouts, 10-20 min after awakening; (6) evidence of developmental delay, intellectual disability, neurological abnormalities, choreoathetosis, and dystonia or ataxia; and (7) not attributable to other disorders. A great effort was made to understand the disease's genetic basis. In 2012, In 2012, two independent research groups -a group of German researchers (9) and an international consortium (10)-identified de novo heterozygous mutations in the ATP1A3 gene performing next-generation sequencing to examine the genome of AHC patients (11). Next, this finding was replicated by an independent Japanese study that found ATP1A

[16] Unraveling Alternating Hemiplegia of Childhood: A Case Report with Genetic and Clinical Insights

  • Authors: Samanwita Mahapatra, Abhishek Singh, Aditi Das, Rohit Bhowmick, N. S. Bhunia et al.
  • Year: 2025
  • Venue: Case Reports in Neurology
  • URL: https://www.semanticscholar.org/paper/f2d89856112f0b3e186567721a338e5858ff2bf7
  • DOI: 10.1159/000548497
  • PMID: 41322064
  • PMCID: 12659400
  • Summary: The need for early recognition and genetic confirmation of AHC to initiate therapy and improve quality of life is highlighted, with flunarizine offering some benefit.
  • Evidence snippets:
  • Snippet 1 (score: 0.419) > Alternating hemiplegia of childhood (AHC) is a complex neurological disorder comprising paroxysmal episodes of repeated, transient paresis involving either or both sides of the body, with onset usually before 18 months [1,2]. The exact pathophysiology remains unknown, but a few postulates point towards energy depletion due to a mutation in the Na + -K + ATPase alpha subunit [3]. Common mutations involve ATP1A3 and ATP1A2; ATP1A3 being the most common [1,2]. The disease most often manifests as a nystagmus, usually involving the ipsilateral eye. Gradually, the infant develops a tonic neck deviation toward the affected side. The disease usually comes to notice when the infant develops flaccid hemiparesis. The weakness usually lasts from a few minutes to hours, and often improves after sleep. The usual precipitating factors are dehydration, stress, and fever. Diagnosis is mainly clinical, with confirmation by genetic analysis. Till now, there is no specific treatment available, but drugs like flunarizine, topiramate, aripiprazole, etc., are shown to reduce the frequency and severity of paroxysms, although the effect on long-term prognosis is still questionable.
  • Snippet 2 (score: 0.419) > Unraveling Alternating Hemiplegia of Childhood: A Case Report with Genetic and Clinical Insights

[17] [Alternating Hemiplegia of Childhood associated with a pathogenic variant of the ATP1A3 gene].

  • Authors: Francisca Sandoval, F. Lopez
  • Year: 2022
  • Venue: Andes pediatrica : revista Chilena de pediatria
  • URL: https://www.semanticscholar.org/paper/c9b47e302ac7ae2580f9fdeb3aa567cfe44cfa98
  • DOI: 10.32641/andespediatr.v93i1.3972
  • PMID: 35856955
  • Summary: The diagnosis of AHC is complex and is frequently confused with epilepsy, so it is important to correctly perform the diagnosis, including anamnesis, tests such as EEG, and careful observation of clinical events that, with the current access to audiovisual technology, becomes more accurate.
  • Evidence snippets:
  • Snippet 1 (score: 0.406) > INTRODUCTION > Alternating hemiplegia of childhood (AHC), is a rare disease characterized by episodes of hemi/quadriplegia, dystonic postures, abnormal eye movements, and movement disorders. ATP1A3 gene mu tations are the most frequently associated with AHC. > OBJECTIVE > To present a clinical case of AHC, where genetic study and the observation of home videos were of great diagnostic utility. > CLINICAL CASE > Female patient who at 3 months of age presented with several episodes of dystonic postures, clonic movements of extremities, cephalic version, and lateral gaze deviation lasting several minutes. Epilepsy was diagnosed and levetiracetam was administrated, without improvement. EEG and brain MRI were performed, with normal results. Therefore, epilepsy was ruled out and transient dystonia of infancy was suspected, however, the events became more frequent, longer in duration, and charac teristically subsided during sleep. Family members provided home videos that clarified the events. At 6 months of age, the patient presented with alternating hemiparesis. Dystonia genetic panel showed a pathogenic variant of the ATP1A3 gene, confirming the diagnosis. Flunarizine treatment was ini tiated with a good clinical response at 12 months of follow-up. > CONCLUSIONS > The diagnosis of AHC is complex and is frequently confused with epilepsy, so it is important to correctly perform the diffe rential diagnosis, including anamnesis, tests such as EEG, and careful observation of clinical events that, with the current access to audiovisual technology, becomes more accurate. The genetic analysis is a great diagnostic tool that, when performed in time, avoids other unnecessary tests and therapies.

Notes

  • This provider combines search_papers_by_relevance with snippet_search.
  • No synthesis or second-stage model call is performed.